The Motley Fool·2026-03-08 12:00Core Insights - The weight loss market is expanding, and while Eli Lilly and Novo Nordisk are current leaders, other companies like Regeneron and Roche are emerging as potential investment opportunities due to their diversified portfolios and innovative products. Group 1: Regeneron - Regeneron reported strong phase 2 results for its weight-loss candidate, trevogrumab, which minimizes muscle loss in patients taking GLP-1 medicines, averting about half of the lean mass loss associated with semaglutide [3][4] - Regeneron's approach allows trevogrumab to be prescribed alongside existing treatments like Wegovy, avoiding direct competition with market leaders [4] - The company is also developing a GLP-1 medicine, olatorepatide, with phase 3 studies expected to start this year, indicating potential for significant clinical progress [6] - Regeneron's primary growth driver is Dupixent, an eczema treatment, and it has a vast pipeline that could lead to additional product launches in the coming years [7] Group 2: Roche - Roche reported strong phase 2 results for its anti-obesity candidate, CT-388, showing a placebo-adjusted weight loss of 22.5% over 48 weeks at the highest dose, positioning it competitively against leading weight-loss drugs [8] - The company is preparing for phase 3 studies to confirm these results, establishing itself as a notable player in the next-generation obesity medicine race [8] - Roche has a diversified healthcare business with several growth drivers in pharmaceuticals, including Ocrevus for multiple sclerosis and Vabysmo, alongside a deep pipeline of 66 new molecular entities [10]